Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
Aged
Aged, 80 and over
Brachytherapy
/ adverse effects
Chemotherapy, Adjuvant
Follow-Up Studies
Humans
Male
Middle Aged
Multivariate Analysis
Organs at Risk
Prostatic Neoplasms
/ drug therapy
Quality of Life
Radiometry
Radiotherapy
/ methods
Radiotherapy Dosage
Rectum
/ radiation effects
Urethra
/ radiation effects
Urinary Bladder
/ radiation effects
Biochemical progression-free survival
High-risk prostate cancer
Radiotherapy
Toxicity
Urinary function
Journal
Japanese journal of radiology
ISSN: 1867-108X
Titre abrégé: Jpn J Radiol
Pays: Japan
ID NLM: 101490689
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
27
04
2020
accepted:
21
07
2020
pubmed:
2
8
2020
medline:
4
5
2021
entrez:
2
8
2020
Statut:
ppublish
Résumé
The purpose of this study was to investigate the clinical outcomes, urinary function, quality of life (QOL), and toxicities in high- or very high-risk prostate cancer patients undergoing single-fraction high-dose-rate brachytherapy (HDR-BT) with external beam radiotherapy (EBRT) and analyze the relationship between dosimetric parameters and toxicities. Between April 2014 and April 2019, 124 patients underwent 13-Gy HDR-BT followed by EBRT (46 Gy/23 fractions). Urinary function and QOL were evaluated using IPSS and 7-grade QOL Scale, respectively. Biochemical progression-free survival (bPFS) was calculated. Median follow-up period was 35.8 months; all patients received neoadjuvant hormonal therapy and very high-risk patients received adjuvant hormonal therapy. Only one patient developed a grade 3 toxicity (hematuria). Multivariate analysis showed the dose covering 30% of the urethral volume, bladder volume receiving 75% of the dose, and dose covering 2 cc of rectum were independent predictors of acute G2 urinary frequency, acute G2 urinary retention, and late G2 rectal hemorrhage. IPSS and QOL scores significantly increased following HDR-BT and returned to baseline within 6 months. The 2-year bPFS was 99.2%. The single-fraction HDR-BT with EBRT is a safe treatment for quicker recovery of urinary symptoms and QOL. The dose of at-risk organs correlated with toxicities. Single-fraction high-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy (EBRT) for prostate cancer is a safe treatment allowing for quicker recovery of urinary symptoms and QOL. The dose of at-risk organs correlated with toxicities.
Identifiants
pubmed: 32737768
doi: 10.1007/s11604-020-01023-2
pii: 10.1007/s11604-020-01023-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1197-1208Commentaires et corrections
Type : ErratumIn
Références
Cancer Statistics in Japan, Center for Cancer Control and Information Services, National Cancer Center. 2020. Available online: https://ganjoho.jp/reg_stat/statistics/stat/summary.html. Accessed Jan 18, 2020
Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117–23.
doi: 10.1200/JCO.2009.26.0133
Mohler JL, Armstrong AJ, Bahnson RR, D’Amico AV, Davis BJ, Eastham JA, et al. Prostate cancer, version 1. 2016. J Natl Compr Canc Netw. 2016;14:19–30.
doi: 10.6004/jnccn.2016.0004
Spratt DE, Soni PD, McLaughlin PW, Merrick GS, Stock RG, Blasko JC, et al. American Brachytherapy Society Task Group Report: combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy. 2017;16:1–12.
doi: 10.1016/j.brachy.2016.09.006
Yamazaki H, Masui K, Suzuki G, Nakamura S, Shimizu D, Nishikawa T, et al. High-dose-rate brachytherapy monotherapy versus image-guided intensity-modulated radiotherapy with helical tomotherapy for patients with localized prostate cancer. Cancers (Basel). 2018;10:E322.
doi: 10.3390/cancers10090322
Falk AT, Demontoy S, Chamorey E, Chand ME, Gautier M, Azria D, et al. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes. Brachytherapy. 2017;16:993–9.
doi: 10.1016/j.brachy.2017.06.013
Hijazi H, Chevallier D, Gal J, Chand ME, Gautier M, Hannoun-Levi JM. Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fractionation schemes. J Contemp Brachytherapy. 2013;5:203–9.
doi: 10.5114/jcb.2013.38657
Lauche O, Delouya G, Taussky D, Menard C, Béliveau-Nadeau D, Hervieux Y, et al. Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results. J Contemp Brachytherapy. 2016;8:104–9.
doi: 10.5114/jcb.2016.59216
Boladeras A, Santorsa L, Gutierrez C, Martinez E, Pera J, Pino F, et al. External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer. Radiother Oncol. 2014;112:227–32.
doi: 10.1016/j.radonc.2014.07.013
Morton GC, Loblaw DA, Sankreacha R, Deabreu A, Zhang L, Mamedov A, et al. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys. 2010;77:811–7.
doi: 10.1016/j.ijrobp.2009.05.054
Pistis F, Guedea F, Pera J, Gutierrez C, Ventura M, Polo A, et al. External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy. 2010;9:15–22.
doi: 10.1016/j.brachy.2009.05.001
Büchser D, Casquero F, Espinosa JM, Perez F, Minguez P, Martinez-Indart L, et al. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study. Radiother Oncol. 2019;135:13–8.
doi: 10.1016/j.radonc.2019.02.018
Martell K, Mendez LC, Chung HT, Tseng CL, Alayed Y, Cheung P, et al. Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: analysis of over 500 patients. Radiother Oncol. 2019;141:149–55.
doi: 10.1016/j.radonc.2019.08.017
Shahid N, Loblaw A, Chung HT, Cheung P, Szumacher E, Danjoux C, et al. Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer. Clin Oncol (R Coll Radiol). 2017;29:412–20.
doi: 10.1016/j.clon.2017.01.042
Chicas-Sett R, Farga D, Perez-Calatayud MJ, Celada F, Roldan S, et al. High-dose-rate brachytherapy boost for prostate cancer: analysis of dose-volume histogram parameters for predicting late rectal toxicity. Brachytherapy. 2017;16:511–7.
doi: 10.1016/j.brachy.2017.03.002
Kragelj B, Zlatic J, Zaletel-Kragelj L. Avoidance of late rectal toxicity after high-dose-rate brachytherapy boost treatment for prostate cancer. Brachytherapy. 2017;16:193–200.
doi: 10.1016/j.brachy.2016.10.008
Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy. 2012;1:20–322.
doi: 10.1016/j.brachy.2011.09.008
Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert FA, et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol. 2013;3:325–32.
doi: 10.1016/j.radonc.2013.05.002
Wilder RB, Chittenden L, Mesa AV, Bunyapanasarn J, Agustin J, Lizarde J, et al. A prospective study of intrafraction prostate motion in the prone vs. supine position. Int J Radiat Oncol Biol Phys. 2010;77:165–70.
doi: 10.1016/j.ijrobp.2009.04.041
Ikeda I, Mizowaki T, Sawada Y, Nakata M, Norihisa Y, Ogura M, et al. Assessment of interfractional prostate motion in patients immobilized in the prone position using a thermoplastic shell. J Radiat Res. 2014;55:168–74.
doi: 10.1093/jrr/rrt089
Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74.
doi: 10.1016/j.ijrobp.2006.04.029
Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Kim Y, Hsu IC, Pouliot J. Measurement of craniocaudal catheter displacement between fractions in computed tomography-based high dose rate brachytherapy of prostate cancer. J Appl Clin Med Phys. 2007;8:2415.
doi: 10.1120/jacmp.v8i4.2415
Tiong A, Bydder S, Ebert M, Caswell N, Waterhouse D, Spry N, et al. A small tolerance for catheter displacement in high-dose rate prostate brachytherapy is necessary and feasible. Int J Radiat Oncol Biol Phys. 2010;76:1066–72.
doi: 10.1016/j.ijrobp.2009.03.052
Yoshida K, Yamazaki H, Nose T, Shiomi H, Yoshida M, Mikami M, et al. Needle applicator displacement during high-dose-rate interstitial brachytherapy for prostate cancer. Brachytherapy. 2010;9:36–41.
doi: 10.1016/j.brachy.2009.04.006
Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50:1021–31.
doi: 10.1016/S0360-3016(01)01607-8
Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13.
doi: 10.1016/S0360-3016(01)02664-5
Löser A, Beyer B, Carl CO, Löser B, Nagaraj Y, Frenzel T, et al. Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer. Strahlenther Onkol. 2019;195:374–82.
doi: 10.1007/s00066-018-1380-5
Tanimoto R, Bekku K, Katayama N, Kobayashi Y, Ebara S, Araki M, et al. Predictive factors for acute and late urinary toxicity after permanent interstitial brachytherapy in Japanese patients. Int J Urol. 2013;20:812–7.
doi: 10.1111/iju.12050
Li X, Fang D, Cooperberg MR, Whitson JM, Lue TF, Zhou L, et al. Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. World J Urol. 2014;32:1061–6.
doi: 10.1007/s00345-013-1188-y
Miyake M, Tanaka N, Asakawa I, Hori S, Morizawa Y, Tatsumi Y, et al. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute. BMC Urol. 2017;17:62.
doi: 10.1186/s12894-017-0251-1
Sanmamed N, Chung P, Berlin A, Adleman J, Borg J, Lao B, et al. Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: impact on acute urinary toxicity and health-related quality of life. Brachytherapy. 2019;18:477–83.
doi: 10.1016/j.brachy.2019.02.003
Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatecomy. Eur Urol. 2007;52:29–37.
doi: 10.1016/j.eururo.2007.04.020
Dirix P, Joniau S, Van den Bergh L, Isebaert S, Oyen R, Deroose CM, et al. The role of elective pelvic radiotherapy in clinically node-negative prostate cancer: a systematic review. Radiother Oncol. 2014;110:45–544.
doi: 10.1016/j.radonc.2013.06.046
Tharmalingam H, Tsang Y, Choudhury A, Alonzi R, Wylie J, Ahmed I, et al. External beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume. Int J Radiat Oncol Biol Phys. 2020;106:525–33.
doi: 10.1016/j.ijrobp.2019.09.044